drugset
drugset / Trial / NCT07505303

MIST (Metabolic Intervention With Semaglutide and THR-β Therapy) Trial

NCT07505303 ↗

Phase 2 Active not recruiting 151 enrolled Eccogene
RandomizedParallel-groupTriple-blindTreatment

Summary

The primary objective of this trial is to evaluate the effect of oral ECC4703 on body weight reduction and in a sub-study on liver fat content as assessed by change in magnetic resonance imaging proton density fat fraction (MRI-PDFF) at Week 20.

Timeline

Start
2026-03-23
Primary completion
2026-10-15
Completion
2026-10-15

Drugs

EvaluationDrugModalityDoseRoute
Subject ECC4703 Unknown — Oral
Background Semaglutide Peptide — Subcutaneous

Indications

obesity disorder